Medifast, Inc.

What they do

Medifast sells scientifically developed meal replacement products and structured plans through a network of independent coaches, supplemented by its Habits of Health habit-creation framework and community support. The company launched the Trilivy metabolic health brand in July 2026, replacing the OPTAVIA identity, and positions its Metabolic Synchronization science as the basis for its plans. Revenue comes primarily from product sales to clients recruited and supported by independent active earning coaches.

Revenue drivers

• Coach-led product sales (formerly OPTAVIA, now Trilivy) — Substantially all revenue comes from sales of meal replacement and metabolic health products to clients of independent active earning coaches; Q2 2026 revenue was $76.4 million.
• Independent coach network — The network of active earning coaches is the primary distribution channel and acquisition engine; it stood at approximately 11,700 coaches at June 30, 2026 due to client acquisition pressure.
• Trilivy Reset product line — Newly launched product line as part of the Trilivy brand; management cited roughly 60 basis points of Q2 2026 SG&A pressure from the launch.
• Revenue per active earning coach — Average revenue per active earning coach was $6,529 in Q2 2026, up 41.0% year over year, reflecting prioritization of more productive coaches despite a smaller network.

Recent performance

Second quarter 2026 revenue fell 27.6% to $76.4 million from $105.6 million a year earlier, primarily on a 48.7% decline in active earning coaches to 11,700. Gross margin was 69.9% versus 72.6%, and SG&A fell 25.7% to $57.7 million but rose to 75.6% of revenue. The company reported a net loss of $3.1 million, or $0.28 per diluted share, and a loss from operations of $4.3 million. Revenue per active earning coach rose 41.0% to $6,529, and the company ended the quarter with $169.8 million in cash, cash equivalents and investment securities and no debt.

Strategy

In October 2025 Medifast announced a strategic transformation toward holistic metabolic health, and in July 2026 launched the Trilivy brand to replace OPTAVIA. Management is focused on improving coach productivity, expanding the coach network, and leveraging Metabolic Synchronization science, the new Reset Fuelings, and the Medifast Metabolic Health Institute. A Catalyst program launched in Q2 2026 targets cost savings through facility rationalization and AI-related efficiencies, with most execution expected in Q3. The company frames these moves as its 3.0 strategy intended to support a return to profitability in the fourth quarter.

Risks

• GLP-1 competition — The 10-K states that growing acceptance of weight loss medications such as GLP-1s has reduced and may further reduce demand for Medifast's services and products.
• Coach network contraction — Active earning coaches fell 48.7% year over year to 11,700 in Q2 2026, and management expects the number to continue declining in 2026.
• Revenue and profitability decline — Revenue fell from $1.53 billion in 2021 to $385.8 million in 2025, with a net loss of $19.0 million in 2025 and a $3.1 million net loss in Q2 2026.
• Loss of operating leverage — Gross margin fell to 69.9% and SG&A rose to 75.6% of revenue in Q2 2026 as fixed costs were spread over a smaller revenue base.

Outlook

Management says it is on track to return to profitability in the fourth quarter of 2026 and describes Q2 as showing signs of a turnaround, with sequentially stable revenue and growth in coach productivity. The company expects the number of active earning coaches to continue to decline in 2026. It is also executing the Catalyst cost-savings program, with most of that execution expected in Q3.